Chocen

• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Pending
  2024-519994-20-00 5 Agitation Associated with Alzheimer’s Disease
• A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending
  2025-521113-13-00 10 Early Parkinson’s Disease
• An Open-Label Study of ML-007C-MA in Adults with Alzheimer’s Disease Psychosis Pending
  2025-521757-16-00 4 Hallucinations and Delusions Associated with Alzheimer’s Disease Psych
• A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending
  2025-524316-11-00 5 Primary Progressive Multiple Sclerosis (PPMS)
• ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting
  2025-521711-39-00 5 2026-05-17 Lewy body Dementia psychosis (LBDP)
• A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults Recruiting
  2024-511101-28-00 4 2026-02-24 Episodic Migraine Chronic Migraine
• A Study of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis Recruiting
  2024-519820-26-00 4 2026-01-22 Hallucinations and Delusions Associated with Alzheimer’s Disease Psych
• ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting
  2025-521710-25-00 4 2025-12-04 Lewy Body Dementia Psychosis (LBDP)
• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease. Recruiting
  2025-520612-34-00 5 2025-11-28 Agitation Associated with Alzheimer’s Disease
• A study of IPN10200 for the treatment of cervical dystonia in adults Recruiting
  2024-519248-34-00 4 2025-06-17 Cervical Dystonia
• This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting
  2023-507351-29-00 5 2024-12-03 Alzheimer's Disease Psychosis
• A study to assess the efficacy and safety of ITI-1284 in the treatment of Agitation Associated with Alzheimer's Dementia Ended recruitment
  2024-514680-26-00 4 2025-07-17 Agitation Associated with Alzheimer’s Dementia
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine Ended recruitment
  2024-512946-41-00 5 2025-03-05 Menstrual Migraine
• ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended recruitment
  2023-507325-42-00 4 2024-07-02 Alzheimer Disease psychosis
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• Randomized, Double-Blind, Placebo-Controlled, Multiple-Attack Study with an Open-Label Extension to Evaluate the Efficacy, Safety, Tolerabil … Ended recruitment
  2023-506029-12-00 5 2024-04-03 Migraine
• A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended recruitment
  2023-504839-40-00 5 2024-03-18 Episodic Migraine
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine … Ended recruitment
  2022-501172-25-00 5 2024-01-17 Chronic and Episodic Migraine
• A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and S … Ended recruitment
  2022-501622-37-00 5 2024-01-16 Multiple Sclerosis
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended
  2023-507096-21-00 5 2021-08-16 Chronic or Episodic Migraine (Migraine without aura, migraine with aur
• A clinical trial which runs in multiple countries and aims to evaluate the long-term safety and tolerability of the investigational product … Ended
  2024-512123-37-00 5 2021-05-27 Parkinson's disease

Showing 1–22 of 22 trials